Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nω-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 5, 2002, Pages 789-800

  De Gasparo, Marc ^a,c   Hess, Patrick ^b   Clozel, Martine ^b   Persohn, Elke ^a   Roman, Danielle ^a   Germann, Paul Georg ^a   Clozel, Jean Paul ^b   Webb, Randy L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c MG Consulting Co   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitor; Endothelium; Histology; N nitro L arginine methyl ester; Nitric oxide synthase; Spontaneously hypertensive rats

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; ENALAPRIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; VALSARTAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; HISTOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CORONARY CIRCULATION; DRUG THERAPY, COMBINATION; ENALAPRIL; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; KIDNEY; MALE; NG-NITROARGININE METHYL ESTER; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRAZOLES; VALINE;

EID: 0036872314     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200211000-00017     Document Type: Article

References (41)

1. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
2. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-4.
3. Mervaala EMA, Cheng ZJ, Tikkanen I, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001;37(part 2):414-8.
4. Jover B, Herizi A, Ventre F, et al. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993;21:944-8.
5. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics. Hypertension 1995;26: 249-55.
6. Ribeiro MO, Antunes E, de Nucci G, et al. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992;20:298-303.
7. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;97:278-87.
8. Katoh M, Egashira K, Usui M, et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998;83:743-51.
9. Usui M, Ichiki T, Katoh M, et al. Regulation of angiotensin II receptor expression by'nitric oxide in rat adrenal gland. Hypertension 1998;32:527-33.
10. 2 antagonist-sensitive potentiation of angiotensin II-induced constriction by NO blockade and its dependence on endothelium and P450 eicosanoids in rat renal vasculature. Br J Pharmacol 1998; 124:946-52.
11. Kashiwagi M, Shinozaki M, Hirakata H, et al. Locally activated renin-angiotensin system associated with TGF-beta 1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-24.
12. Sventek P, Turgeon A, Schiffrin EL. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation 1997;95:240-4.
13. Sventek P, Li JS, Grove K, et al. Vascular structure and expression of endothelin-1 gene in L-NAME treated spontaneously hypertensive rats. Hypertension 1999;27:49-55.
14. Tomita H, Egashira K, O'Hara Y, et al. Early induction of transforming growth factor-b via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998;32:273-9.
15. Takemoto M, Egashira K, Tomita H, et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997;30:1621-7.
16. de Gasparo M, Hess P, Nuesslein-Hildesheim B, et al. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000;2:151-8.
17. Guzik TJ, West NEJ, Black E, et al. Vascular superoxide production by NAAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86:e85-90.
18. Usui M, Egashira K, Kitamoto S, et al. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999;34:546-51.
19. Griffin KA, Picken M, Bidani AK. Radiotelemetric blood pressure monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994;46: 1010-8.
20. 1 receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats. J Cardiovasc Fail 2001;7:269-76.
21. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 1991;18:1137-42.
22. Karam H, Heudes D, Hess P, et al. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 1996;31: 287-95.
23. Li JS, Deng LY, Grove K, et al. Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N-nitro-L-arginine methyl ester: correlation with topography of vascular endothelin-1 gene expression. Hypertension 1996;28: 188-95.
24. Casellas D, Herizi A, Artuso A, et al. Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects. J Renin Angiotensin Aldosterone Syst 2001;2:S84-90.
25. Casellas D, Benehmed S, Artuso A, et al. Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 1999;10(suppl 11):S230-3.
26. Fransischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with or without L-NAME. Hypertension 1998;31:79531-801.
27. Kim S, Yoshiyama M, Izumi Y, et al. Effect of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103:148-54.
28. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, et al. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 2001;16:1343-9.
29. Mervaala E, Müller DN, Schmidt F, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.
30. Moreno H Jr, Nathan LP, Pereira Costa SK, et al. Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur J Pharmacol 1995;287:93-6.
31. Gervais M, Richer C, Fornes P, et al. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635-45.
32. Blythe WB, Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis 1991;18:33-7.
33. Müller DN, Dechend R, Mervaala EMA, et al. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193-201.
34. Mervaala EMA, Müller DN, Park JK, et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999;33:389-95.
35. Scott-Burden T, Resink TJ, Hahn AW, et al. Induction of endothelin secretion by angiotensin II: effects on growth and synthetic activity of vascular smooth muscle cells. J Cardiovasc Pharmacol 1991;17(suppl 7):S96-100.
36. Tharaux PL, Chatziantoniou C, Casellas D, et al. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-91.
37. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:387,1-8.
38. 1 receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. Hypertension 2001;38:404-11.
39. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000;35:1074-7.
40. Nakamura Y, Ono H, Zhou X, et al.-Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001;37: 1262-7.
41. Cao Z, Bonnet F, Davis B, et al. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci 2001;100:591-9.